Efficacy and Safety of the Association of Dexamethasone 0.5 mg + Clemastine Fumarate 1 mg When Compared to Dexamethasone 0.5 mg in Patients With Allergic Dermatitis

Inclusion Criteria:

• Patients who sign the Deed of Consent (IC) in two ways, by his own free will, agreeing with all study procedures;

  • Patients older than 18 years, any ethnicity, class or social group, regardless of sex;
  • Patients with pictures of dermatoses acute, subacute or chronic, of inflammatory origin and / or allergic, to which it is recommended the use of drugs under investigation topically, such as:
• atopic dermatitis,
• prurigo,
• primary contact dermatitis or allergic
• urticaria,
• pharmacodermic,
• allergic vasculitis,
• dyshidrosis,

Exclusion Criteria:

• Patients being treated with antibiotics;
• Participation in clinical trials in the 12 months preceding the survey;
• Current treatment with immunosuppressants (eg, cyclosporine or methotrexate);
• Current treatment with phototherapy (UVA, UVB, PUVA and lasers);
• Use of systemic corticosteroids at inclusion visit or within 15 days prior to inclusion;
• Topical treatments at the site of acne in the 15 days preceding the visit of inclusion;
• Presence of any skin condition in areas affected by acne that hamper the evolutionary analysis of the lesion;
• Presence of secondary infections at the site of treatment, diagnosed clinically;
• Presence of other eczematous picture, such as nummular eczema, neurodermatitis, seborrheic dermatitis, psoriasis, scabies, and Buckley's syndrome Wiskott-Aldrich;
• Pregnant or lactating women;
• Chronic alcoholism;
• Patients with a history of hypersensitivity to any component of the formulas of the products under investigation;
• Any finding of clinical observation (clinical history or physical examination) that is interpreted by the physician investigator as a risk to the patient's participation in the study;
• Allergic Dermatosis of moderate or severe that, according to the investigator, is not justified topical.